Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach

• Main Authors: Panayotis Kaloyannidis, Eshrak Al Shaibani, Asif Moinnudin, Khalid Al Anezi, Hani Al Hashmi
• Format: Article
• Language: English
• Published: PAGEPress Publications 2021-03-01
• Series: Hematology Reports
• Subjects: Allogeneic hematopoietic stem cell transplantation, Hodgkin lymphoma, programmed death-1 (PD-1) inhibitors
• Online Access: https://www.pagepress.org/journals/index.php/hr/article/view/8780

For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity.